Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study
Nephron · 2024 · 148 (1) · 22-33
DOI: 10.1159/000531869 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephron, online erschienen am 20.07.2023. Verfasst von Jun Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: NanFang Hospital of Southern Medical University, Guangzhou City, China. Hauptthemen laut MEDLINE: Hyperphosphatemia, Sucrose. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to investigate the efficacy and safety of sucroferric oxyhydroxide (SFOH) versus sevelamer carbonate in controlling serum phosphorus (sP) in adult Chinese dialysis patients with hyperphosphataemia (sP >1.78 mmol/L).
Methods
Open-label, randomised (1:1), active-controlled, parallel group, multicentre, phase III study of SFOH and sevelamer at starting doses corresponding to 1,500 mg iron/day and 2.4 g/day, respectively, with 8-week dose titration and 4-week maintenance (NCT03644264). Primary endpoint was non-inferiority analysis of change in sP from baseline to week 12. Secondary endpoints included sP over time and safety.
Results
415 patients were screened; 286 were enrolled and randomised (142 and 144 to SFOH and sevelamer, respectively). Mean (SD) baseline sP: 2.38 (0.57) and 2.38 (0.52) mmol/L, respectively. Mean (SD) change in sP from baseline to week 12: – 0.71 (0.60) versus −0.63 (0.52) mmol/L, respectively; difference (sevelamer minus SFOH) in least squares means (95% CI): 0.08 mmol/L (−0.02, 0.18) with the lower limit of 95% CI above the non-inferiority margin of −0.34 mmol/L. The SFOH group achieved target sP (1.13–1.78 mmol/L) earlier than the sevelamer group (56.5% vs. 32.8% at week 4) and with a lower pill burden (mean 3.7 vs. 9.1 tablets/day over 4 weeks of maintenance, respectively). Safety and tolerability of SFOH was consistent with previous studies, and no new safety signals were observed.
Conclusion
SFOH effectively reduced sP from baseline and was non-inferior to sevelamer after 12 weeks of treatment but had a lower pill burden in Chinese dialysis patients with hyperphosphataemia; SFOH benefit-risk profile is favourable in Chinese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NanFang Hospital of Southern Medical University, Guangzhou City, China.
- Peking University People's Hospital, Beijing, China.
- Vifor Pharma Management Ltd., Glattbrugg, Switzerland.
Zitieren
APA
Liu, J., Zuo, L., Walpen, S., Bernard, L., Marty, M., & Enoiu, M. (2024). Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study. Nephron, 148(1), 22-33. https://doi.org/10.1159/000531869
Vancouver
Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study. Nephron. 2024;148(1):22-33. doi:10.1159/000531869
BibTeX
@article{Liu2024,
author = {Liu, Jun and Zuo, Li and Walpen, Sebastian and Bernard, Laurence and Marty, Matthieu and Enoiu, Milica},
title = {Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study},
journal = {Nephron},
year = {2024},
volume = {148},
number = {1},
pages = {22--33},
doi = {10.1159/000531869}
}
EUVIMED